Evidence map›Paper›PMID 26948856›Full record

Trial reportAddiction (Abingdon, England)2016

Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study.

Walter Ling, Maureen P Hillhouse, Andrew J Saxon, Larissa J Mooney, Christie M Thomas, Alfonso Ang, Abigail G Matthews, Albert Hasson, Jeffrey Annon, Steve Sparenborg and 14 more

2 registry-linked trialsAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Addiction (Abingdon, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 40 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 4 pooled it
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01402492 phase2 / phase3completednot on this map

Cocaine Use Reduction With Buprenorphine (CURB)

TypeinterventionalSponsorUniversity of California, Los AngelesRan2011 to 2013Enrolled302ConditionsCocaine DependenceArmsBuprenorphine + Naltrexone, Placebo + Naltrexone
NCT05262270 phase2completednot on this mapstarted 2023, after this paper: background citation

Randomized, Placebo-Controlled Trial of Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2)

TypeinterventionalSponsorUniversity of Texas Southwestern Medical CenterRan2023 to 2025Enrolled427ConditionsCocaine Use DisorderArmsExtended-Release Naltrexone, Extended Release Buprenorphine, Placebo (PLB) Injectable matched to XR-NTX, Placebo (PLB) Injectable matched to XR-BUP
3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 4 syntheses or guidelines pooled it, 67 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 11 institutions in 1 country.

Walter LingUniversity of California, Los Angeles, CA, USA.
Maureen P HillhouseUniversity of California, Los Angeles, CA, USA.
Andrew J SaxonVeterans Affairs Puget Sound Health Care System, Seattle, WA, USA.
Larissa J MooneyUniversity of California, Los Angeles, CA, USA.
Christie M ThomasUniversity of California, Los Angeles, CA, USA.
Alfonso AngUniversity of California, Los Angeles, CA, USA.
Abigail G MatthewsThe Emmes Corporation, Rockville, MD, USA.
Albert HassonUniversity of California, Los Angeles, CA, USA.
Jeffrey AnnonUniversity of California, Los Angeles, CA, USA.
Steve SparenborgNational Institute on Drug Abuse, Bethesda, MD, USA.
David S LiuNational Institute on Drug Abuse, Bethesda, MD, USA.
Jennifer McCormackThe Emmes Corporation, Rockville, MD, USA.
Sarah ChurchAlbert Einstein College of Medicine, Bronx, NY, USA.
William SwaffordAddiction Research and Treatment Services (ARTS), Denver, CO, USA.
Karen DrexlerAtlanta VA Medical Center, Atlanta, GA, USA.
Carolyn SchumanBAART Programs, San Francisco, CA, USA.
Stephen RossBellevue Hospital Center, New York, NY, USA.
Katharina WiestCODA, Portlad, OR, USA.
P Todd KorthuisOregon Health and Science University, Portland, OR, USA.
William LawsonHoward University, Washington, DC, USA.
Gregory S BrighamMaryhaven Treatment Center, Columbus, OH, USA.
Patricia C KnoxRecovery Centers of King County (RCKC), Kent, WA, USA.
Michael DawesSouth Texas Veterans Health Care System, San Antonio, TX, USA.
John RotrosenNew York University School of Medicine, New York, NY, USA.
University of California, Los Angeles · USEmmes (United States) · USNational Institute on Drug Abuse · USAlbert Einstein College of Medicine · USAtlanta VA Medical Center · USBellevue Hospital Center · USHoward University · USNew York University · USOregon Health & Science University · USSouth Texas Veterans Health Care System · USVA Puget Sound Health Care System · US

Funding

Project-003UG1DA013035 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Aimee N Campbell, Jennifer McNeely · 2015 to 2026
$130.3M
Project-004UG1DA020024 · NIDA · UT SOUTHWESTERN MEDICAL CENTER · PI Steven J Shoptaw, MADHUKAR H. TRIVEDI · 2015 to 2026
$71.6M
The National Drug Abuse Treatment Clinical Trials NetworkU10DA013045 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LING, WALTER NMN · 1999 to 2015
$52.6M
CU PARTNERS: NY/LONG ISLAND REGIONAL NODEU10DA013035 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI NUNES, EDWARD V., ROTROSEN, JOHN P · 2001 to 2015
$47.6M
Western States Node of the National Drug Abuse Treatment Clinical Trials NetworkU10DA015815 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MCCARTY, DENNIS, SORENSEN, JAMES L · 2002 to 2015
$25.2M
Western States Node of the National Drug Abuse Treatment Clinical Trials Network (TMS for CUD) UG1DA015815 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Keith N. Humphreys, Philip Todd Korthuis · 2015 to 2026
$24.6M
Concept ProjectU10DA020024 · NIDA · UT SOUTHWESTERN MEDICAL CENTER · PI TRIVEDI, MADHUKAR H. · 2005 to 2015
$22.6M
NIDA CLINICAL TRIALS NETWORK - NYC EAST SIDE NODEU10DA013046 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ROTROSEN, JOHN P · 2000 to 2009
$20.2M
Clinical Trials Network: Pacific Northwest Node (CTN-0082, -0131, -0139 and dissemination library)UG1DA013714 · NIDA · UNIVERSITY OF WASHINGTON · PI Mary Akiko Hatch, John M. Roll · 2015 to 2026
$19.8M
NIDA NIH HHS HHSN271200900034CNIDA NIH HHS HHSN271201200017CNIDA NIH HHS HHSN271201400028CNIDA NIH HHS U10 DA013035NIDA NIH HHS U10 DA013045NIDA NIH HHS U10 DA013046NIDA NIH HHS U10 DA015815NIDA NIH HHS U10 DA020024NIDA NIH HHS UG1 DA013035NIDA NIH HHS UG1 DA013714NIDA NIH HHS UG1 DA015815NIDA NIH HHS UG1 DA020024
6 · The paper itself

Abstract

aimsTo examine the safety and effectiveness of buprenorphine + naloxone sublingual tablets (BUP, as Suboxone(®) ) provided after administration of extended-release injectable naltrexone (XR-NTX, as Vivitrol(®) ) to reduce cocaine use in participants who met DSM-IV criteria for cocaine dependence and past or current opioid dependence or abuse.

methodsThis multi-centered, double-blind, placebo-controlled study, conducted under the auspices of the National Drug Abuse Treatment Clinical Trials Network, randomly assigned 302 participants at sites in California, Oregon, Washington, Colorado, Texas, Georgia, Ohio, New York and Washington DC, USA to one of three conditions provided with XR-NTX: 4 mg/day BUP (BUP4, n = 100), 16 mg/day BUP (BUP16, n = 100, or no buprenorphine (placebo; PLB, n = 102). Participants received pharmacotherapy for 8 weeks, with three clinic visits per week. Cognitive behavioral therapy was provided weekly. Follow-up assessments occurred at 1 and 3 months post-intervention. The planned primary outcome was urine drug screen (UDS)-corrected, self-reported cocaine use during the last 4 weeks of treatment. Planned secondary analyses assessed cocaine use by UDS, medication adherence, retention and adverse events.

resultsNo group differences were found between groups for the primary outcome (BUP4 versus PLB, P = 0.262; BUP16 versus PLB, P = 0.185). Longitudinal analysis of UDS data during the evaluation period using generalized linear mixed equations found a statistically significant difference between BUP16 and PLB [P = 0.022, odds ratio (OR) = 1.71] but not for BUP4 (P = 0.105, OR = 1.05). No secondary outcome differences across groups were found for adherence, retention or adverse events.

conclusionsBuprenorphine + naloxone, used in combination with naltrexone, may be associated with reductions in cocaine use among people who meet DSM-IV criteria for cocaine dependence and past or current opioid dependence or abuse.

Indexed as

Administration, OralAdultAnalgesics, OpioidBuprenorphine, Naloxone Drug CombinationCocaine-Related DisordersCognitive Behavioral TherapyDelayed-Action PreparationsDouble-Blind MethodFemaleHumansInjections, IntramuscularMaleMiddle AgedNaltrexoneNarcotic AntagonistsTreatment OutcomeAnalgesics, OpioidBuprenorphine, Naloxone Drug CombinationDelayed-Action PreparationsNaltrexoneNarcotic AntagonistsBuprenorphine + naloxonecocaine use disorderdouble-blindmulti-site trialnaltrexonepharmacotherapyplacebo-controlledtreatment

Identifiers

PMID26948856
PMCPMC4940267
OpenAlexW2293959932

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.